Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.40 |
| ▸ | BTK | Q06187 | 4/20 | 0.39 |
| ▸ | ITK | Q08881 | 4/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29481417 | 0.81 | PRMT5 (0.48) | F2KLKB1MAP4K1BTKITK | |
| SCHEMBL7443703 | 0.81 | PRMT5 (0.48) | F2KLKB1MAP4K1BTKITK | |
| SCHEMBL23452595 | 0.80 | KLKB1 (0.50) | F2KLKB1MAP4K1BTKITK | |
| Hydrochloric Acid SCHEMBL29485586 | 0.80 | PRMT5 (0.47) | F2KLKB1MAP4K1BTKITK | |
| Hydrochloric Acid SCHEMBL16881193 | 0.80 | PRMT5 (0.47) | F2KLKB1MAP4K1BTKITK | |
| Hydrochloric Acid SCHEMBL7213801 | 0.80 | PRMT5 (0.47) | F2KLKB1MAP4K1BTKITK | |
| SCHEMBL23491251 | 0.77 | KLKB1 (0.48) | F2KLKB1MAP4K1BTKITK | |
| SCHEMBL27033400 | 0.77 | CYP3A4 (0.43) | KLKB1MAP4K1ITKPRMT5WDR77 | |
| SCHEMBL23279795 | 0.77 | F2 (0.47) | F2KLKB1MAP4K1BTKITK | |
| SCHEMBL29958152 | 0.77 | CYP3A4 (0.43) | KLKB1MAP4K1ITKPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611252-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-04-04 | — | — | US | disclosed |
| WO-2017001924-A1 | THERAPEUTIC INHIBITORY COMPOUDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-01-05 | — | — | WO | disclosed |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | F2 75/4885KLKB1 1/4885MAP4K1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.